DRUG INDUCED HEMOLYTIC ANEMIA: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.47820/recima21.v3i12.2463Keywords:
Hemolytic Anemia, Hemolysis, MedicinesAbstract
Drug-induced hemolytic anemia (AHIM) is a rare complication, resulting from the interaction of certain substances with the erythrocyte membrane, which can be fatal if not quickly elucidated. The anemia can occur in response to the use of any drug therapy and is often underdiagnosed. Thus, the present study aims to carry out a systematic review of the literature on drug-induced hemolytic anemia in the PubMed, Virtual Health Library (BVS) and Capes Periodicals published in the last five years. During the study, 19 scientific articles were selected in the present review, of which 18 were case reports and 1 was a retrospective study. It was observed that in only one study, the clinical outcome resulting from the AHIM was the death of the patient. Altogether, the research revealed 19 active principles related to drug-induced hemolysis.
Downloads
References
Al-Ansari RY, KHURAIM AA, Abdalla L, Hamid H, Zakary NY. Remsima (a Tumor Necrosis Factor (TNF)-α Inhibitor) induced hemolysis in a patient with Crohn's disease-Case report. Ann. Med. Surg. 2021;69(1):102768.
Mioti AGX, De Castro GFP. Alterações hematológicas induzidas por anti-inflamatórios não-esteroidais. Rev. Transformar. 2017;10(1):170-183
Mohammad S, Clowse MEB, Eudy AM, Criscione-Schreiber LG. Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6 PDH‐Deficient Patients. Arthritis Care Res; 2018;70(3):481-485.
Wu Y, Wu, Y, Yang Y, Chen B, Li J, Guo G, Xiong F. Case Report: First Case of Cefotaxime-Sulbactam-Induced Acute Intravascular Hemolysis in a Newborn With ABO Blood Type Incompatibility by the Mechanism of Non-Immunologic Protein Adsorption. Frontiers in immunology. 2021;12:698541.
Belfield KD, Tichy EM. Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency. Am J Health Syst Pharm. 2018;75(3):97-104,
Afra F, Mehri M, Namazi S. Bosentan-induced immune hemolytic anemia in 17 years old man. A case report. DARU Journal of Pharmaceutical Sciences. 2021; 29(1):211-215.
Agbuduwe C, Rugless M, Asba N, Proven M, Sivakumaran M. Severe drug-induced hemolysis in a patient with compound heterozygosity for Hb Peterborough (HBB: c. 334G> T) and Hb Lepore-Boston-Washington (NG_000007. 3: g. 63632_71046del). Hemoglobin, 2019;43(1): 56-59.
Gniadek TJ, Arndt PA, Leger RM, Zydowicz D, Cheng EY, Zantek ND. Drug‐induced immune hemolytic anemia associated with anti‐vancomycin complicated by a paraben antibody. Transfusion. 2018;58(1):181-188.
Quintanilla-Bordás C, Castro-Izaguirre E, Carcelén-Gadea M, Marín M. The first reported case of drug‐induced hemolytic anemia caused by dimethyl fumarate in a patient with multiple sclerosis. Transfusion. 2019;59(5):1648-1650.
Esteves A, Silva FT, Carvalho J, Carvoeiro A, Falgueiras P. Diclofenac-Induced Immune Hemolytic Anemia: A Case Report and Review of Literature. Cureus. 2021;13(1):e12903.
Gomez JC, Saleem T, Snyder S, Joseph M, Kanderi T. Drug-induced immune hemolytic anemia due to amoxicillin-clavulanate: a case report and review. Cureus. 2020;12(6):e8666.
Nguyen, TN, Maenulein E, Fihman V, Vinatier I, Moh Klaren J. Serologic characteristics of oxaliplatin antibodies in 15 patients with drug‐induced immune hemolytic anemia. Transfusion. 2021;61(5):1609-1616.
Wu S, Jing L, Feng Y, Chen L. Marked reduction in haemoglobin levels secondary to ceftizoxime-induced immune haemolytic anaemia in diabetic patients. J Clin Pharm Ther. 2020;45(4):812-814.
Dara RC, Sharma R, Bhardwaj H. Severe drug-induced immune hemolysis due to ceftriaxone. Asian J. Transfus. Sci. 2020;14(2)187-191.
Hamid NC, Malek KA, Nasir NM, Nasir NM. Pneumocystis jirovecii Pneumonia with a Normal Early Chest Radiography and Complicated with Drug-Induced Immune Hemolytic Anemia: A Case Report. The American Journal of Case Reports. 2022;23:e936278-1.
HIill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017;177(2):208-220.
Havey TC, Cserti-Gazdewich C, Sholzberg M, Keystone JS, Gold WL. Case report: recurrent disseminated intravascular coagulation caused by intermittent dosing of rifampin. Am J Trop Med. 2012;86(2):264-267.
Sanwal C, Kaldas A, Surani S, Bailey M. Rifampin-Induced Acute Intravascular Hemolysis Leading to Heme Pigment-Related Kidney Injury. Cureus. 2020;12(7):e9120.
Stevens-Cohen P, Zaghi F, Zhu L. A Rare Case of Hydrochlorothiazide-Induced Hemolytic Anemia. Cureus. 2021;13(8):e17453.
Johnson ST, Fueger JT, Gottschal JL. One center's experience: the serology and drugs associated with drug‐induced immune hemolytic anemia—a new paradigm. Transfusion. 2007;47(4):697-702, 2007.
BAE, Ju Young et al. Anemia hemolítica Coombs-negativa em um homem com COVID-19. Relatos de Casos Clínicos , v. 9, n. 7, pág. e04503, 2021.
Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology. 2014;30(2);66-79.
Gong JH, Liu GJ, Zhou F, Sun ZQ. Dabigatran-induced chronic progressive immune hemolytic anemia: A case report. J. Stroke Cerebrovasc. Dis. 2020;29(8):1-2.
Ishii H, Sato T, Ishibashi M, Yokoyama H, Saito T, Tasaki T, et al. A case of immune complex type hemolytic anemia by initial micafungin administration. Int J Infect Dis. 2022;0(0):755–757.
Wu Y, Wu Y, Ji Y, Liu Y, Wu D, Liang J, et al. Case Report: Oral Cimetidine Administration Causes Drug-Induced Immune Hemolytic Anemia by Eliciting the Production of Cimetidine-Dependent Antibodies and Drug-Independent Non-specific Antibodies. Front Med. 2021;8:1–9
Lois TAE, López-Polín A, Norman FF, Monge-Maillo B, López-Vélez, R, Perez-Molina JA. Delayed haemolysis secondary to treatment of severe malaria with intravenous artesunate: Report on the experience of a referral centre for tropical infections in Spain. Travel medicine and infectious disease. 2017;15:52–56.
Fanello C, Onyamboko M, Lee SJ, Woodrow C, Setaphan S, Chotivanick K et al. Post-treatment haemolysis in African children with hyperparasitaemic falciparum malaria; a randomized comparison of artesunate and quinine. BMC Infect. Dis. 2017;17(1):575-583.
Camprubí D, Pereira A, Rodriguez-Valero N, Almuedo A, Varo R, Calsas-Pascual C et al. Positive direct antiglobulin test in post-artesunate delayed haemolysis: more than a coincidence? Malar. J. 2019;18(1)128-135.
Savargaonkar D, Das MK, Verma A, Miltra JK, Yadav CP, Srivastava B. Delayed haemolysis after treatment with intravenous artesunate in patients with severe malaria in India. Malar J. 2020;19(1):39-45.
Lo YH, MOK K. L. High dose vitamin C induced methemoglobinemia and hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency. Am J Emerg Med. 2020;38(11):2488.e3-2488.e5.
Maillart E, Leemans S, Van Noten H, Vandergraesen T, Mahadeb B, Salaouatchi MT et al. A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine. Infect Dis. 2020;52(9):659–61.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2022 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
